dentsu health Merges Antibody into Canadian Business

Atlas Antibodies Acquires HistoCyte Laboratories Ltd

February 1, 2021

Medical Devices

Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

DAS Health Acquires North American Digital Health Division from Canadian Provider

July 9, 2024

Healthcare Services

DAS Health Ventures (a Sheridan Capital Partners portfolio company) acquired the North American Digital Health division of an established Canadian digital transformation provider, giving DAS Health a footprint in Canada and expanding its senior care-focused health IT capabilities. The division adds managed IT, cybersecurity, cloud hosting, integrations, and revenue cycle management services to DAS Health's offerings as an add-on to its existing platform.

Dentsu Group Acquires Tag from Advent International

March 7, 2023

Marketing & Advertising

Dentsu Group Inc. has agreed to acquire Tag, a global omnichannel marketing production company, from private equity firm Advent International. Tag, which operates a proprietary marketing execution platform (Digital Interact) and employs ~2,800 people across 29 countries, will become part of dentsu's network to expand its content production and technology-enabled marketing capabilities.

Fortis Life Sciences Acquires Abcore

March 2, 2022

Biotechnology

Fortis Life Sciences has acquired Abcore, an antibody discovery platform specializing in nanobody technologies, to expand Fortis’ antibody product and service capabilities. The acquisition brings Abcore’s end-to-end discovery and custom antibody production capabilities into the Fortis platform to accelerate commercial and operational scale-up for biopharma and diagnostic customers.